BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19814696)

  • 1. Approach to the patient after relapse of hairy cell leukemia.
    Kreitman RJ; Fitzgerald DJ; Pastan I
    Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
    Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunobiological treatments of hairy-cell leukaemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2003 Mar; 16(1):117-33. PubMed ID: 12670470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxins in the treatment of refractory hairy cell leukemia.
    Kreitman RJ; Pastan I
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
    Robak T
    Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoconjugates and new molecular targets in hairy cell leukemia.
    Kreitman RJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
    Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I
    N Engl J Med; 2001 Jul; 345(4):241-7. PubMed ID: 11474661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
    Kreitman RJ
    Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the biology and treatment options for hairy cell leukemia.
    Jain P; Pemmaraju N; Ravandi F
    Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
    Kreitman RJ; Pastan I
    Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
    Kreitman RJ; Pastan I
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
    Tallman MS; Zakarija A
    Transfus Apher Sci; 2005 Feb; 32(1):99-103. PubMed ID: 15737878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hairy cell leukemia variant.
    Robak T
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hairy cell leukemia: present and future directions.
    Kreitman RJ
    Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hairy cell leukemia: an elusive but treatable disease.
    Wanko SO; de Castro C
    Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
    Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
    Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
    Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
    Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. My treatment approach to hairy cell leukemia.
    Naik RR; Saven A
    Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.